An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

KPG-121, a novel cereblon modulator, in patients with metastatic castration resistant prostate cancer: Results of a phase I multiple ascending dose study. Baseline PSMA PET/CT as a predictive ...

It is difficult to escape a genitourinary malignancies session at any major oncology meeting these days without hearing a proclamation that the technetium-99 (Tc99) bone scan is dead. The triumphant ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

CIRT leads to temporary urinary function decline, normalizing within three months and stable for five years. Prostate volume decreases significantly without ADT, remaining reduced for five years. T ...

Prostate cancer highlights from the American Urological Association 2025 meeting include quality-of-life results from the phase 3 PSMAfore study, findings on androgen deprivation therapy (ADT) with or ...